Cargando…

Avatrombopag, an oral thrombopoietin receptor agonist: results of two double‐blind, dose‐rising, placebo‐controlled Phase 1 studies

Avatrombopag is an oral thrombopoietin receptor agonist that has been recently approved for treating thrombocytopenia in chronic liver disease patients needing invasive procedures. Clinical trials supporting this new treatment were guided by two double‐blind, dose‐rising, placebo‐controlled Phase 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuter, David J., Allen, Lee F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282597/
https://www.ncbi.nlm.nih.gov/pubmed/30203841
http://dx.doi.org/10.1111/bjh.15574